Unknown

Dataset Information

0

PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.


ABSTRACT: Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting 68Ga-RM2 with the prostate-specific membrane antigen (PSMA)-targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients underwent both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 (n = 23) or 18F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUVmax was collected for all lesions. Results: 68Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. 68Ga-PSMA11/18F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: 68Ga-RM2 detected 7 more lesions in 4 patients, whereas 68Ga-PSMA11/18F-DCFPyL detected 36 more lesions in 13 patients. Conclusion: 68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.

SUBMITTER: Baratto L 

PROVIDER: S-EPMC8612333 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.

Baratto Lucia L   Song Hong H   Duan Heying H   Hatami Negin N   Bagshaw Hilary P HP   Buyyounouski Mark M   Hancock Steven S   Shah Sumit S   Srinivas Sandy S   Swift Patrick P   Moradi Farshad F   Davidzon Guido G   Iagaru Andrei A  

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20210305 11


Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting <sup>68</sup>Ga-RM2 with the prostate-specific membrane antigen (PSMA)-targeting <sup>68</sup>Ga-PSMA11 and <sup>18</sup>F-DCFPyL. <b>Methods:</b> Fifty patients underwent both <sup>68</sup>Ga-RM2 PET/MRI and <sup>68</sup>Ga-PSMA11 (<i>n</i> = 23) or <sup>18</sup>F-DCFPyL (<i>n</i> = 27) PET/CT at an interva  ...[more]

Similar Datasets

| S-EPMC8973291 | biostudies-literature
| S-EPMC6771040 | biostudies-literature
| S-EPMC11645485 | biostudies-literature
| S-EPMC5605480 | biostudies-literature
| S-EPMC7442090 | biostudies-literature
| S-EPMC7983162 | biostudies-literature
| S-EPMC7537873 | biostudies-literature
| S-EPMC10461474 | biostudies-literature
| S-EPMC10582101 | biostudies-literature
2014-07-10 | E-GEOD-55323 | biostudies-arrayexpress